잠시만 기다려 주세요. 로딩중입니다.

미국, 유럽, 일본의 의약품 시판 후 안전관리제도 현황: 위해성 관리 계획을 중심으로

Current Status of Post-marketing Safety Management in United States, Europe and Japan: Risk Management Plan

약물역학위해관리학회지 2020년 12권 2호 p.70 ~ 78
김선하, 김희진, 최남경,
소속 상세정보
김선하 ( Kim Seon-Ha ) - Ewha Womans University College of Science and Industry Convergence Department of Health Convergence
김희진 ( Kim Hee-Jin ) - Ewha Womans University College of Science and Industry Convergence Department of Health Convergence
최남경 ( Choi Nam-Kyong ) - Ewha Womans University College of Science and Industry Convergence Department of Health Convergence

Abstract


Since the limitations of pre-marketing clinical trials, "whole life-cycle managements" that confirm the safety and effectiveness of drugs from the development stage to the post-marketing stage is being emphasized. The United States, Europe, and Japan established risk management systems that reflected the 'E2E: Pharmacovigilance Planning' announced by the International Council of Harmonization (ICH). Based on the E2E guideline, the US Food and Drug Administration (FDA) strengthened the FDA Amendments Act (FDAAA) to provide a legal basis for Post-Marketing Requirement (PMR) and Risk Evaluation and Mitigation Strategy (REMS). The European Medicines Agency (EMA) established Good pharmacoVigilance Practices (GVP) to implement the current form of Risk Management Plan (RMP). In Japan, it was suggested that they should implement RMP based on the case of the adverse event of fibrinogen preparation, and Pharmaceuticals and Medical Device Agency (PMDA) introduced RMP. This paper addresses the post-marketing safety management focusing on RMP in the United States, Europe and Japan, and compare the examples of RMPs of each country for the same drug.

키워드

Risk management plan; Risk evaluation and mitigation strategy; Real-world data; Post-authorization safety study

원문 및 링크아웃 정보

등재저널 정보